Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Airway Obstruction D000402 13 associated lipids
Uremia D014511 33 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Canales A et al. The effect of consuming meat enriched in walnut paste on platelet aggregation and thrombogenesis varies in volunteers with different apolipoprotein A4 genotype. 2010 Sep-Oct Nutr Hosp pmid:21336431
Fuchs I et al. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. 2010 Crit. Care Med. pmid:20400900
Steib CJ et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. 2010 Lab. Invest. pmid:20212458
Dragani A et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 2010 Blood pmid:19887674
Kienzler JL et al. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. 2010 J Clin Pharmacol pmid:19841157
Würtz M et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. 2010 Heart pmid:19910291
Koeberle A et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. 2010 J. Pharmacol. Exp. Ther. pmid:19934399
Armstrong PC et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. 2010 J. Thromb. Haemost. pmid:19995405
Nørregaard R et al. Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue. 2010 Am. J. Physiol. Regul. Integr. Comp. Physiol. pmid:20147610
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Dragani A et al. Clinical and laboratory phenotype associated with the aspirin-like defect. 2010 Br. J. Haematol. pmid:19814736
Maddens BE et al. Validation of immunoassays for the candidate renal markers C-reactive protein, immunoglobulin G, thromboxane B2 and retinol binding protein in canine urine. 2010 Vet. Immunol. Immunopathol. pmid:19815297
Derhaschnig U et al. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. 2010 Platelets pmid:20608787
Cheng Y and Li ZK [Changes of neurotransmitter endothelin, thromboxance B2 and 6-keto-prostaglandin F1 alpha in patients with chronic pulmonary heart disease]. 2010 Nan Fang Yi Ke Da Xue Xue Bao pmid:20584647
Boutaud O and Oates JA Study of inhibitors of the PGH synthases for which potency is regulated by the redox state of the enzymes. 2010 Methods Mol. Biol. pmid:20645166
Kawaguchi T et al. The human megakaryocytic cell line UT-7/TPO expresses functional platelet agonist signals mediated through GPVI and thromboxane receptor. 2010 Cell Biol. Int. pmid:20522022
King JN et al. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. 2010 Res. Vet. Sci. pmid:20004922
Zisman E et al. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. 2010 Eur J Anaesthesiol pmid:20035230
Butler BD et al. Circadian study of decompression sickness symptoms and response-associated variables in rats. 2010 Chronobiol. Int. pmid:20205563
Oldenhof J et al. Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. 2010 Curr Med Res Opin pmid:20429831
Boizel R et al. Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes. 2010 Diabetologia pmid:20535444
Liu H et al. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. 2010 Cardiovasc Drugs Ther pmid:19997773
Cavalca V et al. Simultaneous quantification of 8-iso-prostaglandin-F(2alpha) and 11-dehydro thromboxane B(2) in human urine by liquid chromatography-tandem mass spectrometry. 2010 Anal. Biochem. pmid:19825360
Parmar JH et al. Significant prostacyclin/thromboxane level imbalance after lower limb arterial angioplasty: a possible platelet function alteration. 2010 J Vasc Interv Radiol pmid:20800778
Dharmasaroja PA and Sae-Lim S Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. 2010 Blood Coagul. Fibrinolysis pmid:20689403
Kawabata K et al. Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction. 2010 J. Cardiovasc. Pharmacol. pmid:20625313
Milara J et al. Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. 2010 Br. J. Pharmacol. pmid:20698855
Anauate MC et al. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay. 2010 Phytother Res pmid:20812280
Yassine HN et al. Clinical determinants of aspirin resistance in diabetes. 2010 Diabetes Res. Clin. Pract. pmid:20719400
Würtz M et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. 2010 JACC Cardiovasc Interv pmid:20723855
Kim SY et al. Platelet anti-aggregation activities of compounds from Cinnamomum cassia. 2010 J Med Food pmid:20828311
Bao YM et al. [Effect of precondition with GBE50 and Salviae miltionrrhizae on cycloxygenase-2 and its downstream effectors contents in ischemia/reperfusion myocardium]. 2010 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:21066890
De la Cruz JP et al. Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. 2010 Anesth. Analg. pmid:21048099
Qu C et al. Chronic inhibition of nitric-oxide synthase potentiates endothelium-dependent contractions in the rat aorta by augmenting the expression of cyclooxygenase-2. 2010 J. Pharmacol. Exp. Ther. pmid:20444882
Renda G et al. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. 2010 Haematologica pmid:21123440
Iagoda AV and Gladkikh NN [Thromboxane-prostacyclin balance and platelet aggregability in patients with minor cardiac abnormalities]. 2010 Ter. Arkh. pmid:21086621
Warner JH et al. Adaptive regression modeling of biomarkers of potential harm in a population of U.S. adult cigarette smokers and nonsmokers. 2010 BMC Med Res Methodol pmid:20233412
Fukushima H et al. Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin. 2010 Am. J. Med. Genet. A pmid:20583254
Sato R et al. Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model. 2010 Exp. Lung Res. pmid:20426527
Wang BZ et al. [Association of the Pro1770Leu polymorphism in CYP5A1 gene with myocardial infarction in Uigur population of Xinjiang]. 2010 Zhonghua Yi Xue Yi Chuan Xue Za Zhi pmid:20931532
Huang HC et al. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. 2010 J. Gastroenterol. Hepatol. pmid:20659230
Wang BZ et al. [Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang]. 2010 Zhonghua Yu Fang Yi Xue Za Zhi pmid:21215134
Ge Y et al. [Effect of ulinastatin on thromboxane Bâ‚‚ and deep vein thrombosis in elderly patients after hip joint replacement]. 2010 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:21200097
Ferrante E et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. 2010 Free Radic. Biol. Med. pmid:20541603
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Iwasaki W et al. Changes in the fatty acid composition of the liver with the administration of N-3 polyunsaturated fatty acids and the effects on warm ischemia/reperfusion injury in the rat liver. 2010 Shock pmid:19543146
Yen PL et al. Effects of deep-frying oil on blood pressure and oxidative stress in spontaneously hypertensive and normotensive rats. 2010 Nutrition pmid:19592221
Huntjens DR et al. Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. 2010 Eur J Pain pmid:19679500
Santilli F et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 2010 J. Thromb. Haemost. pmid:20088941
Yao HX et al. [The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]. 2010 Zhonghua Yi Xue Za Zhi pmid:20356540